The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- Millions in vaccine research funds went instead for unrelated office expenses, HHS inspector general sayson January 27, 2021 at 11:05 am
Millions of dollars in federal funds earmarked for vaccine development and other public health matters were wrongly used for the removal of office furniture, news subscriptions and other ...
- Antibodies periodically wax and wane in survivors of Ebolaon January 27, 2021 at 10:18 am
But an immediate implication is that, because anti-Ebola antibody levels wane between bouts of resurgence, recurrent vaccine boosters in survivors (in addition to heightened surveillance) might be ...
- Ebola virus antibody decay–stimulation in a high proportion of survivorson January 27, 2021 at 8:02 am
In many survivors of Ebola virus infection, antibody responses show long-term patterns of decline followed by restimulation, possibly owing to recrudescence of persisting virus.
- Antibody highs and lows in survivors of Ebolaon January 27, 2021 at 8:01 am
A high proportion of survivors of Ebola experienced a resurgence in antibody levels nearly a year after recovery, a new University of Liverpool study has found.
- Shropshire Ebola hero now gearing up to help deliver coronavirus vaccineson January 26, 2021 at 10:06 pm
A Shropshire medic who helped out in Africa at the height of an Ebola epidemic was delighted to get his first dose of the coronavirus vaccine this week.
- Merck is halting research on its Covid-19 vaccines. Here's why.on January 26, 2021 at 8:32 am
Merck on Monday announced that it will stop developing its two Covid-19 vaccine candidates, citing data indicating that the experimental vaccines prompted inadequate immune responses. Separately, ...
- Devil is in the details: A new stockpile for Ebola vaccineson January 26, 2021 at 4:13 am
As vaccines against the COVID-19 pandemic begin to be rolled-out around the world – albeit almost exclusively in rich countries for the moment – there is another piece of good news about a vaccine ...
- Merck Stops Developing Both Of Its COVID-19 Vaccine Candidateson January 25, 2021 at 10:51 am
Merck, which previously made an Ebola vaccine, had been seen as a serious contender in the worldwide race to come up with an answer to the coronavirus.
- Merck discontinuing development of two COVID-19 vaccine candidateson January 25, 2021 at 5:06 am
Merck has halted its development of two potential vaccines for the coronavirus, citing data that showed a lack of immune response, ...
- UNICEF, WHO, IFRC and MSF Announce the Establishment of a Global Ebola Vaccine Stockpileon January 20, 2021 at 3:46 pm
The effort to establish the stockpile was led by the International Coordinating Group (ICG) on Vaccine Provision, which includes the World Health Organization (WHO), UNICEF, the International ...
via Google News and Bing News